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Abstract 
Objectives  
Xpert MTB/RIF (Cepheid) is a rapid molecular assay shown to be sensitive and specific for 
pulmonary tuberculosis (TB) diagnosis in highly endemic countries. We evaluated its 
diagnostic performance in a low TB prevalence setting, examined rifampicin resistance 
detection and quantitative capabilities predicting graded auramine microscopy and time to 
positivity (TTP) of culture. 
Methods 
Xpert MTB/RIF was used to test respiratory samples over a 3 year period. Samples 
underwent graded auramine microscopy, solid/ liquid culture, in-house IS6110 real-time 
PCR, and GenoType MTBDRplus (HAIN Lifescience) to determine rifampicin and/or 
isoniazid resistance.  
Results 
A total of 2103 Xpert MTB/RIF tests were performed. Compared to culture sensitivity was 
95.8%, specificity 99.5%, positive predictive value (PPV) 82.1%, and negative predictive 
value (NPV) 99.9%. A positive correlation was found between auramine microscopy grade 
and Xpert MTB/RIF assay load. We found a clear reduction in the median TTP as Xpert 
MTB/RIF assay load increased. Rifampicin resistance was detected. 
Conclusions 
Xpert MTB/RIF was rapid and accurate in diagnosing pulmonary TB in a low prevalence 
area. Rapid results will influence infection prevention and control and treatment measures. 
The excellent NPV obtained suggests further work should be carried out to assess its role in 
replacing microscopy.  
Abstract Word Count 198 
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Introduction 
Diagnosing tuberculosis (TB) can be problematic as patients may present with a wide range 
of symptoms which may not be specific.  In addition, the sensitivity of microscopy and smear 
positivity in respiratory TB ranges from 57-81%, potentially leading to misdiagnosis.1 TB 
culture is the gold standard for diagnosing TB and allows drug susceptibilities to be tested. 
There have been developments in rapid automated mycobacterial liquid culture systems and 
time to detection of growth of mycobacterial species can be shortened significantly.2 Even 
with these advances there could be delays in diagnosis, leading to later initiation of 
appropriate therapy and implementation of infection prevention and control measures.  
Xpert MTB/RIF (Cepheid) is a rapid, direct molecular test for the diagnosis of pulmonary TB 
and detection of rifampicin (RIF) resistance, which is a marker of multidrug resistant TB 
(MDRTB).3 It has been endorsed by the World Health Organisation (WHO) and extensive 
evaluation has found it to be sensitive and specific for pulmonary TB diagnosis and detection 
of RIF resistance in high endemic countries for suspected cases of MDRTB.4 Xpert MTB/RIF 
has lower sensitivity in HIV-associated TB.5 There is however, considerably less data on the 
use of Xpert MTB/RIF in low prevalence countries despite increased use.6 Recently a study 
to examine the use of Xpert MTB/RIF versus AFB smear and culture to identify pulmonary 
TB found that the diagnostic performance of Xpert MTB/RIF in the United States was similar 
to higher TB prevalence sites in Brazil and South Africa.7 
 
Scotland’s TB incidence was 6.5 cases per 100,000 population in 2014 with low rates of 
MDR-TB (around 0.9%).8  In that year, Scotland  had an estimated rate of 1.51 
diagnosed HIV-infected persons per 1000 population  in adults aged 15-59 years (Glenn 
Codere, Health Protection Scotland, Personal Communication 14 December 2016). The UK 
National Institute for Health and Care Excellence (NICE) guidance recommends rapid 
diagnostic nucleic acid amplification tests for diagnosing pulmonary (including laryngeal) TB 
in adults if there is clinical suspicion of TB disease and the person has HIV or in 
circumstances in which rapid information about mycobacterial species would alter the 
persons care or in a situation where a large contact-tracing initiative is being explored.9 Other 
guidance advises rapid detection of MDRTB is also recommended on the basis that filtering 
face piece (FFP3) masks respiratory protection should be used until MDRTB has been 
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excluded.10  The Public Health England (PHE) position statement published in July 2013 
states that molecular testing of M. tuberculosis complex (MTBC) on respiratory samples is 
superior to smear microscopy for the diagnosis of TB  and should be accessible in all areas of 
Scotland, England and Wales with results available within 1 - 2 working days of the sample 
being taken.11  
 
The objective of this study was to evaluate the performance of Xpert MTB/RIF for detection 
of pulmonary TB in patients from the Tayside region of Scotland which has a low TB and 
HIV prevalence. In addition we aimed to examine the quantitative capabilities of  Xpert 
MTB/RIF in relation to predicting auramine stain grading, as well as looking at TTP of 
culture. 
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Materials and Methods 
Study Design and clinical samples 
This is a retrospective review and analysis of data collected for clinical purposes. Respiratory 
samples (sputum, bronchoalveolar lavage (BAL), induced sputum, and endotracheal aspirates 
(ETA)) were submitted over a 3 year period (February 2011 to March 2014) and tested by 
Xpert MTB/RIF at the Department of Medical Microbiology, Ninewells Hospital and 
Medical School, Dundee (NHD).  Samples came from both hospital inpatient and community 
settings and were sent for graded auramine smear microscopy and culture using solid 
Löwenstein-Jensen (LJ) media (containing pyruvate as a growth supplement) and BACTEC 
MGIT 960 liquid media at the Scottish Mycobacteria Reference Laboratory (SMRL) at the 
Royal Infirmary of Edinburgh.  
 
Xpert MTB/RIF  
At NHD, a minimum of 1 ml raw sputum or BAL was collected from samples. Xpert TB/RIF 
was performed on a GeneXpert instrument with GX2.1 software (GX) according to the 
manufacturer’s instructions. A 2ml volume of sample reagent was added to each sample and 
shaken vigorously 10-20 times. This was incubated for 15 minutes at room temperature. At a 
point between 5-10 minutes of incubation the sample was shaken vigorously again 10-20 
times. The liquefied sample was aspirated into a sterile transfer pipette until the meniscus was 
above the minimum mark then added to the Xpert MTB/RIF cartridge and then run on the 
machine according to the manufacturer’s instructions. The GeneXpert DX System interpreted 
Xpert MTB/RIF results depending on the cycle threshold (Ct) value of MTB target present in 
the sample. When MTB was detected results were displayed as high (Ct <16), medium (Ct 
16-22), low (Ct 22-28) or very low (Ct >28). These are known as the Xpert MTB/RIF assay 
load. Negative results were displayed as MTB not detected. Rifampicin resistance was 
reported as either detected, not detected or indeterminate. 
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Sample processing 
Respiratory samples were sent to SMRL where they were liquefied and concentrated using 
Sputasol (1:1 v/v; Oxoid) and a loopful of sediment used to prepare a smear for auramine 
phenol microscopy using standard laboratory methods.12 The number of AFB present was 
scored as: + (few AFB, one to 10 bacilli in 10 fields), ++ (moderate AFB, one to 10 bacilli 
per field) or +++ (many AFB, 10 or more bacilli per field). Specimen decontamination was 
performed with 2% NaOH-NALC and the pellet resuspended in 1.5ml phosphate buffer. 
0.5ml was used to inoculate both a LJ with pyruvate slope and a BACTEC MGIT 960 tube 
(Becton Dickinson) and 0.5ml was stored at -20oC for further additional molecular testing 
where appropriate.  
 
Culture identification 
Cultured mycobacteria were identified using GenoType® MTBC GenoType® Mycobacteria 
CM v1.0 or GenoType® Mycobacteria AS v1.0 (HAIN Lifescience) following the 
manufacturer’s instructions.13,14 MGIT and LJ cultures were considered to have a negative 
result if no mycobacterial growth was seen after 6 or 12 weeks of incubation respectively.  
All MTBC-positive specimens were tested for resistance to RIF and INH using GenoType® 
MTBDRplus v1.0 and v2.0 (HAIN Lifescience) to confirm the Xpert RIF-resistance result 
and confirmed by phenotypic methods.15,16 
Statistical analysis 
Clinical and laboratory data were stored in Microsoft Excel analysed using simple descriptive 
methods in IBM SPSS version 23. Consecutive samples from the same patient were included 
in our analysis. The sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of Xpert MTB/RIF were calculated with 95% confidence intervals 
(CI).17 Chi-squared test for trend was used to compare proportions across ordered categories. 
A Kruskal-Wallis test was used to compare the distributions of times to positivity between 
subgroups. 
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Ethics Approval 
Caldicott guardian approval was gained from NHS Tayside in order to enable appropriate 
information sharing and protect the confidentiality of patients. 
Results 
Performance of Xpert MTB/RIF  
A total of 2103 Xpert MTB/RIF tests were performed on samples from 1299 patients (Figure 
1).  The number of samples per patient ranged from 1 to 14, with a median of 1. A total of 38 
samples were invalid on Xpert MTB/RIF testing (19 sputum, 15 BAL, 3 ETA and 1 induced 
sputum). A further 79 samples had insufficient material for further testing. Of the 1986 
remaining samples, 35 were contaminated on culture, leaving 1951 samples from 1211 
patients that received both Xpert MTB/RIF and culture (1141 sputa, 754 BAL, 51 ETA and 5 
induced sputa).  
In total 48 (2.5%) grew MTBC and 1903 were MTBC- negative using culture (97.5%). Of the 
1903 MTBC-negative samples, 97 grew non-tuberculous mycobacteria (NTM) and no MTB 
was detected using Xpert MTB/RIF. If culture is used as the gold standard, the overall 
sensitivity of Xpert MTB/RIF was 95.8%, specificity 99.5%, PPV 82.1%, and NPV 99.9%. 
(Table 1) 
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Figure 1. Overview of Xpert MTB/RIF Tests and Cultures Performed 
 
 
  
 
 
 
 
 
 
  
2103 Xpert MTB/RIF tests 
performed  (1299 patients) 
1951 samples with both culture and 
Xpert MTB/RIF results for analysis 
(1211 patients) 
1986 samples available for 
culture 
38 samples invalid on Xpert 
MTB/RIF testing 
79 samples with insufficient 
material for further analysis 
35 samples contaminated 
on culture 
2065 valid samples   
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Table 1. Overall Performance Characteristics of Xpert MTB/RIF For All Respiratory 
Samples 
Xpert MTB/RIF vs. Culture Number 
detected/Total 
Estimate % 95% CI 
Sensitivity 46/48 95.8% 86.0, 98.8% 
Specificity 1893/1903 99.5% 99.0, 99.7% 
PPV 46/56 82.1% 70.2, 90.0% 
NPV 1893/1895 99.9% 99.6, 100.0% 
 
Of note, two false negative Xpert MTB/RIF results from two different patients were obtained. 
The first patient had four sputa and one BAL which were all AFB smear-negative with no 
MTB detected using Xpert MTB/RIF. All showed no mycobacterial growth except from a 
sputum that grew MTB at 21 days. Interestingly, lymph node tissue from this patient was 
AFB smear positive with MTB detected by in-house IS6110 PCR (Ct 25.1) and culture at the 
reference laboratory. The other patient had a sputum sample that was AFB smear negative 
with no MTB detected using Xpert MTB/RIF but grew MTB at 25 days. In addition two 
other sputa collected at this time were AFB smear negative but Xpert MTB/RIF positive then 
subsequently grew MTB. Approximately 3 months after the study period this patient had 
further sputa which were AFB smear-positive and grew MTB. 
Two BAL and 8 sputum produced false-positive Xpert MTB/RIF results (6 with low level 
and 4 with very low levels of MTB detected) from 7 different patients. Of these, six patients 
had one false-positive Xpert MTB/RIF result and one patient had four false-positive Xpert 
MTB/RIF results. Five patients had MTB detected in subsequent sputum samples which grew 
MTB. For the remaining two patients, one had 3 sputa AFB smear- and culture-negative. One 
of the samples had a low reading (give Ct 26.9) using Xpert MTB/RIF, but no MTB detected 
from a subsequent sputum. The reference lab direct in-house IS6110 PCR was MTBC- 
positive and clinically the chest radiograph and CT scan was suggestive of infection such as 
TB. This patient received a full course of TB therapy with a good response. The last patient 
had 4 sputum submitted which were AFB smear- and culture-negative and  two citrated blood 
samples that did not grow mycobacteria. The Xpert MTB/RIF result for a BAL from this 
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patient was very low (give Ct 33.3).  They responded to standard antibiotic treatment for 
pneumonia and following review in the infectious disease clinic after admission it was 
decided there was no good evidence the patient had TB. It appears therefore that this patient 
had a true false-positive Xpert MTB/RIF result.  
For the 51 ETA and 5 induced sputum all cultures were MTBC negative. The sensitivity, 
specificity, NPV, PPV and 95% confidence interval (CI) of Xpert MTB/RIF for sputum and 
BAL samples is shown in Table 2.Within those with a culture result available, the PPV 
increased with the increasing category of the Xpert MTB/RIF assay load results. 
Table 2. Sensitivity, Specificity, NPV, PPV of Xpert MTB/RIF for Sputum and BAL 
Samples 
Xpert 
MTB/RIF  
vs. Culture 
Sputum 
numbers 
Estimate
% 
95% CI BAL 
numbers 
Estimate
% 
95% CI 
Sensitivity 41/43 95.3% 84.5, 98.7% 5/5 100.0% 56.6, 100.0% 
Specificity 1090/1098 99.3% 98.6, 99.6% 747/749 99.7% 99.0, 99.9% 
PPV 41/49 83.7% 71.0, 92.7% 5/7 71.4% 35.9, 91.8% 
NPV 1090/1092 99.8% 99.3, 99.9% 747/747 100.0% 99.5, 100.0% 
 
Detection of Rifampicin Resistance 
One patient in the study was diagnosed with multi-drug resistant (MDR) TB using direct 
GenoType MTBDRplus at SMRL. Although two wild-type rpoB bands were not detected, no 
mutation was identified using this assay suggesting that another rpoB mutation was present to 
confer resistance. Nine samples submitted from this patient were found to contain MTB by 
Xpert MTB/RIF and the presence of a rpoB mutation was indicated by reduced binding of 
Probe B during PCR resulting in a >3.5 Ct spread between the earliest and latest Ct values. 
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Xpert MTB/RIF and Microscopy 
Overall there were 1927 samples in which microscopy was carried out. It can be seen in 
Table 3 and Figure 2 that there is a clear positive relationship between AFB microscopy 
grade and the Xpert MTB/RIF assay load results even when 97 atypical mycobacteria are 
included. Of these there were 57 non-tuberculous mycobacteria (NTM) with no AFB seen on 
microscopy, 20 with few AFB seen on microscopy, and 20 with moderate AFB seen on 
microscopy. The percentages in the upper two microscopy groups increased as the Xpert 
MTB/RIF assay load results increased, from 0%, 0% and 47.0%, to 84.6%. A chi-squared test 
for trend confirmed the statistical significance of these findings (p<0.001).    
Table 3. Acid Fast Bacilli Microscopy and Xpert MTB/RIF Assay Load Results 
Xpert MTB/RIF assay 
load results 
Microscopy 
grouped 
Negative 
(no 
AFB) 
P+ (few 
AFB) 
P++ 
(moderate 
AFB) 
P+++ 
(many 
AFB) 
Total 
MTB not detected Count 1825 
(57 
atypical) 
23 
( 20 
atypical) 
20 
(20 
atypical) 
3 1871 
 Percentage 97.5 1.2 1.1 0.2 100.0 
Very low Count 6 3 0 0 9 
 Percentage 66.7 33.3 0.0 0.0 100.0 
Low Count 10 7 0 0 17 
 Percentage 58.8 41.2 0.0 0.0 100.0 
Medium Count 2 7 3 5 17 
 Percentage 11.8 41.2 17.6 29.4 100.0 
High Count 1 1 2 9 13 
 Percentage 7.7 7.7 15.4 69.2 100.0 
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Total Xpert MTB/RIF 
assay load results 
Count 1844 41 25 17 1927 
 Percentage 95.7 2.1 1.3 0.9 100.0 
 
Figure 2. Relationship between Xpert MTB/RIF Assay Load and AFB Microscopy 
Results 
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Xpert MTB/RIF and TTP 
We examined time to positivity (TTP) in the 48 culture positive samples (Table 4).  This 
ranged from 6 to 56 days and was highly positively skewed. The median TTP was 10 days. 
There was a clear reduction in the median TTP as the Xpert MTB/RIF assay load results 
increased. A Kruskal-Wallis test comparing times to positivity in the Cepheid PCR categories 
showed a significant difference with p=0.005.  
 
Table 4. Xpert MTB/RIF assay load results and TTP 
Xpert 
MTB/RIF 
assay load 
results 
Samples 
with 
MTB/RIF 
result 
available 
Number 
of 
samples 
culture 
positive 
Median 
TTP 
(days) 
 
Percentile 
25 
Percentile 75 
MTB NOT 
DETECTED 
1974 2 23 21 25 
VERY LOW 9 5 16 15 20 
LOW 17 11 12 8 21 
MEDIUM 17 17 10 9 14 
HIGH 13 13 7 6 8 
 
Conclusion 
We believe this study reports the results of the largest number of Xpert MTB/RIF tests 
carried out in a low prevalence area to date. Taking culture as the gold standard, the overall 
sensitivity of Xpert MTB/RIF was 95.8%, specificity 99.5%, PPV 82.1%, and NPV 99.9%.  
 
In this study, the Xpert MTB/RIF had a sensitivity and specificity of 95.3% and 99.3% 
respectively when used on sputum samples. These figures are similar to previously reported 
studies in high prevelence areas.6 The sensitivity of Xpert MTB/RIF on BAL specimens was 
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found to be 100.0% which is higher in comparison to the findings of a previous study where 
is was found to be 81.6%.18 A recent study involving the Xpert MTB/RIF in Canada found it 
had a sensitivity of 46% and specificity of 100% for detection of MTB from induced sputum 
samples. The authors concluded that paucibacillary disease and dilution of the sample in the 
process of sputum induction may have accounted for its low sensitivity.19 There were small 
numbers of ETA and induced sputum submitted all of which were culture-negative. In 
particular the 5 induced sputa were sampled from 5 different patients. This could be said to 
have been observed as having 100% specificity but we cannot say if this would be true using 
a larger number of samples 
 
The percentage of samples which were invalid using Xpert MTB/RIF was 1.8% (a total of 38 
samples).  Invalid results indicate that the sample processing control (SPC) has failed because 
the sample was either not properly processed or PCR was inhibited. In real life comparisons 
of methods there may be invalid results which can affect the usefulness of tests. Our rate of 
invalids was lower than previously reported.19 
 
It has previously been described that the Xpert MTB/RIF is not specific for the detection of 
rifampicin resistance as silent mutations in the rpoB gene can give rise to the detection of 
false-positive rifampicin resistance.20 We cannot comment on whether false positive readings 
can arise from silent mutations as we only found one patient who had MDRTB.  Xpert 
MTB/RIF detected rifampicin resistance in 9/9 samples and this was confirmed by the 
reference laboratory's standard methods.  Another limitation of this study is that we cannot 
provide the HIV status of the Xpert MTB/RIF tested patients. 
 
We found a clear positive relationship between AFB microscopy grade and the Xpert 
MTB/RIF assay load results and this was statistically significant (p<0.001). Additionally, a 
clear reduction in the median TTP as the Xpert MTB/RIF assay load results increased was 
found. A Kruskal–Wallis test comparing distributions of times to positivity in the Xpert 
MTB/RIF categories showed a significant difference (p=0.005).  These results support similar 
findings from previous studies.21,22 Molecular testing performed directly on respiratory 
samples is likely to be appropriate for the assessment of infectivity and  Xpert MTB /RIF has 
recently been approved for infection prevention and control use in the United States. A 2-
specimen Xpert strategy was found to be most efficient in minimizing airborne infection 
isolation time while identifying all TB cases among individuals with presumptive TB.23 We 
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believe we found only one true false positive Xpert MTB/RIF result from a patient who had 
consolidation on chest radiograph and adrenal lesions for 5 years however they responded to 
standard treatment for pneumonia. In low prevalence TB settings false positives should be 
expected. They can lead to significant clinical and public health implications as it did in this 
case in which a problem assessment group meeting was held with the local Health Protection 
Team. 
 
Our results suggest that Xpert MTB/RIF could provide accurate results in low TB prevalence 
settings. In particular, this assay had a very good NPV which could be useful for ruling out a 
diagnosis of pulmonary TB. Serious consideration should be given to using Xpert MTB/RIF 
as a replacement for microscopy in low prevalence situations. Delays in transport of samples 
to reference laboratories can detrimentally affect culture results. Introducing molecular tests 
such as Xpert MTB/RIF potentially leads to production of rapid results which would enable 
earlier detection or exclusion of pulmonary TB and can be used to influence treatment 
decisions and  appropriate infection prevention and control measures. Molecular testing for 
detection of MTBC performed directly on respiratory samples has the potential to be superior 
to smear microscopy for the diagnosis of TB, although culture should remain the gold 
standard; essential for subsequent drug susceptibility testing and MTBC genotyping.  
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Highlights 
• Xpert MTB/RIF gave accurate results in a low TB and HIV prevalence setting 
• It had a very good NPV useful for ruling out pulmonary TB 
• Auramine microscopy grade and Xpert MTB/RIF assay load correlated 
• Median TTP reduced as Xpert MTB/RIF assay load increased 
• Molecular testing respiratory samples may be appropriate for infectivity assessment 
 
 
